Antibody persistence and safety after heterologous boosting with orally aerosolised Ad5-nCoV in individuals primed with two-dose CoronaVac previously: 12-month analyses of a randomized controlled trial

Antibody persistence and safety after heterologous boosting with orally aerosolised Ad5-nCoV in individuals primed with two-dose CoronaVac previously: 12-month analyses of a randomized controlled trial

Antibody persistence and safety up to 12 months of heterologous orally administered adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in individuals who were primed with two-dose inactivated SARS-CoV-2 vaccine (CoronaVac) previously, has not been reported yet. This randomized, open-label, s...

Full description

Bibliographic Details
Main Authors: Lairun Jin, Rong Tang, Shipo Wu, Xiling Guo, Haitao Huang, Lihua Hou, Xiaoqin Chen, Tao Zhu, Jinbo Gou, Jin Zhong, Hongxing Pan, Lunbiao Cui, Yin Chen, Xin Xia, Jialu Feng, Xue Wang, Qi Zhao, XiaoYu Xu, Zhuopei Li, Xiaoyin Zhang, Wei Chen, Jingxin Li, Fengcai Zhu
Format: Article
Language:English
Published: Taylor & Francis Group 2023-12-01
Series:Emerging Microbes and Infections
Subjects:
COVID-19 vaccines
booster dose
long-term immunity
heterologous
orally administration
Online Access:https://www.tandfonline.com/doi/10.1080/22221751.2022.2155251

Internet

https://www.tandfonline.com/doi/10.1080/22221751.2022.2155251

Similar Items